PharmAthene Inc (NYSEMKT:PIP) : Traders are bullish on PharmAthene Inc (NYSEMKT:PIP) as it has outperformed the S&P 500 by a wide margin of 13.45% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.17%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.47% in the last 1 week, and is up 15.28% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have rallied 29.02% from its 1 Year high price. On Jul 8, 2016, the shares registered one year high at $2.57 and the one year low was seen on Sep 29, 2015. The 50-Day Moving Average price is $2.30 and the 200 Day Moving Average price is recorded at $2.01.
The stock has recorded a 20-day Moving Average of 7.4% and the 50-Day Moving Average is 8.06%.
PharmAthene Inc (NYSEMKT:PIP): The stock was completely flat for the day, closing at $2.49 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $2.50, the stock touched an intraday high of $2.57 and a low of $2.46. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $2.49. The total trading volume on Friday was 687,427.
In an insider trading activity,The director of Pharmathene, Inc, Richman Eric I sold 329,354 shares at $2.2 on April 13, 2016. The Insider selling transaction had a total value worth of $724,579. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Pharmathene, Inc. (Pharmathene) is a biodefense company. The Company is engaged in the development of medical counter measures against biological and chemical threats. The Company has several biodefense candidates in its portfolio: Anthrax vaccines, including SparVax, which is a second generation liquid recombinant protective antigen (rPA) anthrax vaccine, and a lyophilized anthrax vaccine containing rPA; rBChE (recombinant butyrylcholinesterase) bioscavenger, which is a medical counter measure for nerve agent poisoning by organophosphorous (OP) compounds, including nerve gases and pesticides, and Valortim, which is a fully human monoclonal antibody for the prevention and treatment of anthrax infection. The Company develops Valortim in collaboration with Bristol-Myers Squibb (BMS).